| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Revenue | $3.7M | +219.7% |
| Cost of Revenue | $5.4M | +117.7% |
| Gross Profit | -$1.7M | -27.2% |
| R&D Expense | $16.9M | -30.8% |
| SG&A Expense | $26.0M | -30.3% |
| Operating Income | -$44.5M | +29.3% |
| Pre-tax Income | -$48.5M | +24.6% |
| Net Income | -$46.6M | +22.6% |
| EPS (Basic) | -$0.69 |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.7M | -59.0% |
| Short-term Investments | $2.3M | -90.2% |
| Accounts Receivable | $710K | +122.6% |
| Inventory | $2.4M | +13.6% |
| Current Assets | $16.0M | -63.5% |
| Total Assets | $30.1M | -47.2% |
| Current Liabilities | $5.0M | -56.8% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$38.2M | +31.8% |
| Capital Expenditures | $5.9M | +2.4% |
| Investing Cash Flow | $14.9M | +221.8% |
| Financing Cash Flow | $16.6M | -61.4% |
| Free Cash Flow | -$44.1M | +28.6% |
| +62.1% |
| EPS (Diluted) | -$0.69 | +62.1% |
| Total Liabilities |
| $15.7M |
| -47.2% |
| Stockholders' Equity | $13.6M | -45.8% |